• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

医护人员接种BNT162b2 mRNA新冠疫苗加强针的短期安全性

Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers.

作者信息

Paran Yael, Saiag Esther, Spitzer Avishay, Angel Yoel, Yakubovsky Michal, Padova Hagit, Ben-Ami Ronen, Goldinger Ilana, Gamzu Ronni, Sprecher Eli, Zeltser David, Henig Oryan

机构信息

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Department of Infectious Diseases and Infection Control, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

出版信息

Open Forum Infect Dis. 2021 Dec 31;9(3):ofab656. doi: 10.1093/ofid/ofab656. eCollection 2022 Mar.

DOI:10.1093/ofid/ofab656
PMID:35165656
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8755369/
Abstract

This study demonstrated a favorable short-term safety profile after a third dose of the BNT162b2 vaccine among healthcare workers (HCWs). There were more frequent local reactions and less systemic reactions compared to the second dose. The HCWs who reported reactions had higher prebooster titer of anti-S1 antibodies compared to those who reported no reactions.

摘要

本研究表明，医护人员（HCW）接种第三剂BNT162b2疫苗后具有良好的短期安全性。与第二剂相比，局部反应更频繁，全身反应更少。报告有反应的医护人员与未报告有反应的医护人员相比，加强免疫前抗S1抗体滴度更高。

相似文献

1
Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers.医护人员接种BNT162b2 mRNA新冠疫苗加强针的短期安全性
Open Forum Infect Dis. 2021 Dec 31;9(3):ofab656. doi: 10.1093/ofid/ofab656. eCollection 2022 Mar.
2
Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.韩国医护人员接种 ChAdOx1 nCoV-19 疫苗和 BNT162b2 疫苗第一针后的不良反应。
J Korean Med Sci. 2021 May 3;36(17):e115. doi: 10.3346/jkms.2021.36.e115.
3
Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.腺病毒载体 ChAdOx1 疫苗和 BNT162b2 疫苗引起的抗体反应比较。
J Korean Med Sci. 2021 Nov 29;36(46):e311. doi: 10.3346/jkms.2021.36.e311.
4
Evaluation of Prevalence of Side-Effects Associated with Booster Dose of mRNA-Based COVID-19 Vaccine Among Healthcare Workers in Eastern Province, Saudi Arabia: A Descriptive Cross-Sectional Study.沙特阿拉伯东部省份医护人员中基于mRNA的新冠疫苗加强剂量相关副作用患病率评估：一项描述性横断面研究
Infect Drug Resist. 2022 Aug 9;15:4335-4346. doi: 10.2147/IDR.S374265. eCollection 2022.
5
Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose.从未感染过的医护人员，与先前感染过的医护人员相比，在接种第二剂 BNT162b2 mRNA COVID-19 疫苗后三个月，其中和抗体衰减更快。
Int J Infect Dis. 2021 Nov;112:40-44. doi: 10.1016/j.ijid.2021.08.052. Epub 2021 Sep 2.
6
Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data.mRNA-BNT162b2、mRNA-1273 和 ChAdOx1 nCoV-19 疫苗在医护人员中预防 COVID-19 的有效性：基于监测数据的观察性研究。
Clin Microbiol Infect. 2021 Nov;27(11):1699.e5-1699.e8. doi: 10.1016/j.cmi.2021.06.043. Epub 2021 Jul 13.
7
Clinical characteristics of healthcare workers with SARS-CoV-2 infection after vaccination with BNT162b2 vaccine.接种 BNT162b2 疫苗后感染 SARS-CoV-2 的医护人员的临床特征。
BMC Infect Dis. 2022 Jan 28;22(1):97. doi: 10.1186/s12879-022-07083-1.
8
Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.在意大利养老院工作人员样本中，间隔四周接种两剂BNT162b2疫苗后，中和抗SARS-CoV-2抗体滴度及报告的不良反应情况。
Vaccines (Basel). 2021 Jun 15;9(6):652. doi: 10.3390/vaccines9060652.
9
Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.韩国医护人员中第二剂 BNT162b2 mRNA COVID-19 疫苗的不良反应。
J Korean Med Sci. 2021 May 31;36(21):e153. doi: 10.3346/jkms.2021.36.e153.
10
Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.接种BNT162b2或ChAdOx1新冠疫苗的医护人员血清抗体反应比较及不良反应分析
Vaccines (Basel). 2021 Nov 24;9(12):1379. doi: 10.3390/vaccines9121379.

引用本文的文献

1
The prevention and treatment of COVID-19 in patients treated with hemodialysis.COVID-19 的防治在血液透析治疗患者中的应用。
Eur J Med Res. 2023 Oct 9;28(1):410. doi: 10.1186/s40001-023-01389-9.
2
Serologic Response and Safety after a Third Dose of the COVID-19 BNT162b2 Vaccine in Patients with Inflammatory Bowel Diseases.炎症性肠病患者接种第三剂 COVID-19 BNT162b2 疫苗后的血清学反应及安全性
Vaccines (Basel). 2023 Jul 20;11(7):1263. doi: 10.3390/vaccines11071263.
3
Identification of genes related to immune enhancement caused by heterologous ChAdOx1-BNT162b2 vaccines in lymphocytes at single-cell resolution with machine learning methods.

本文引用的文献

1
Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response.BNT162b2疫苗不良反应的发生与SARS-CoV-2 IgG抗体反应增强有关。
Vaccines (Basel). 2021 Sep 1;9(9):977. doi: 10.3390/vaccines9090977.
2
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.BNT162b2 mRNA 新冠疫苗在全国范围内使用的安全性。
N Engl J Med. 2021 Sep 16;385(12):1078-1090. doi: 10.1056/NEJMoa2110475. Epub 2021 Aug 25.
3
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.
利用机器学习方法在单细胞分辨率下鉴定与异源 ChAdOx1-BNT162b2 疫苗引起的淋巴细胞免疫增强相关的基因。
Front Immunol. 2023 Mar 2;14:1131051. doi: 10.3389/fimmu.2023.1131051. eCollection 2023.
4
Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers.日本医护人员接种第三剂BNT162b2新冠疫苗后抗刺突IgG抗体的动态变化
Heliyon. 2022 Dec;8(12):e12125. doi: 10.1016/j.heliyon.2022.e12125. Epub 2022 Dec 7.
5
Adverse Reactions after the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine among Medical School Residents in a Regional Reference University Hospital in Italy.意大利一所地区性参考大学医院医学院住院医师接种第三剂BNT162b2 mRNA新冠疫苗后的不良反应
Vaccines (Basel). 2022 Oct 22;10(11):1779. doi: 10.3390/vaccines10111779.
6
Correlation of Postvaccination Fever With Specific Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 BNT162b2 Booster and No Significant Influence of Antipyretic Medication.接种疫苗后发热与针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）BNT162b2加强针的特异性抗体反应的相关性以及退热药的无显著影响
Open Forum Infect Dis. 2022 Sep 23;9(10):ofac493. doi: 10.1093/ofid/ofac493. eCollection 2022 Oct.
7
Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination.根据之前的mRNA新冠疫苗接种情况，对mRNA-1273加强针的反应原性。
Vaccines (Basel). 2022 Jul 29;10(8):1217. doi: 10.3390/vaccines10081217.
8
Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine rollout in a multi-site healthcare system.对基于 mRNA 的 COVID-19 疫苗的犹豫和不良反应-多站点医疗保健系统中疫苗推出的早期经验。
PLoS One. 2022 Aug 5;17(8):e0272691. doi: 10.1371/journal.pone.0272691. eCollection 2022.
9
Risk Factors and Incidence Rates of Self-Reported Short-Term Adverse Events of COVID-19 Vaccine Booster Dose.新冠疫苗加强针自我报告的短期不良事件的风险因素及发生率
Vaccines (Basel). 2022 Jul 13;10(7):1115. doi: 10.3390/vaccines10071115.
10
Antibody Responses after Two Doses of COVID-19 mRNA Vaccine in Dialysis and Kidney Transplantation Patients Recovered from SARS-CoV-2 Infection.SARS-CoV-2 感染康复的透析和肾移植患者接种两剂 COVID-19 mRNA 疫苗后的抗体反应。
Medicina (Kaunas). 2022 Jul 3;58(7):893. doi: 10.3390/medicina58070893.
SARS-CoV-2 mRNA 疫苗可诱导持久的人体生发中心反应。
Nature. 2021 Aug;596(7870):109-113. doi: 10.1038/s41586-021-03738-2. Epub 2021 Jun 28.
4
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.以色列全国疫苗接种运动后，mRNA BNT162b2疫苗对SARS-CoV-2感染及COVID-19病例、住院和死亡的影响与效果：一项利用国家监测数据的观察性研究
Lancet. 2021 May 15;397(10287):1819-1829. doi: 10.1016/S0140-6736(21)00947-8. Epub 2021 May 5.
5
Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.BNT162b2 疫苗接种与医护人员中出现有症状和无症状 SARS-CoV-2 感染的相关性。
JAMA. 2021 Jun 22;325(24):2457-2465. doi: 10.1001/jama.2021.7152.
6
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study.英国COVID症状研究应用程序使用者接种疫苗后的疫苗副作用和SARS-CoV-2感染：一项前瞻性观察研究。
Lancet Infect Dis. 2021 Jul;21(7):939-949. doi: 10.1016/S1473-3099(21)00224-3. Epub 2021 Apr 27.
7
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
8
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.